350 FIFTH AVENUE, NEW YORK, NY
VP of Finance John Militello Resigns; Joseph Manhede Appointed Principal Acco...
Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Stockholders Elect Seven Directors at Rocket Pharmaceuticals Annual Meeting
Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Announces $180 Million Sale of Priority Review Voucher
Annual Report to Security Holders
FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals Enters $100 Million Sales Agreement with Cantor Fitzge...
FY 2024
Q3
Q2
Q1
SC TO-I
Tender Offer Statement by Issuer
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement